Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840915 · ClinicalTrials.gov registry record · Phase 1
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03840915 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 70 participants.
The verdict
NCT03840915, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840915
The ClinicalTrials.gov registry entry for NCT03840915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03840915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840915 about?
NCT03840915 is a clinical study titled "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)". The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
What is the current status of trial NCT03840915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2019-04-02. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT03840915?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03840915?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.